APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Executive Order No. 14017, America's Supply Chains (February 24, 2021), provisions relating to strengthening domestic manufacturing of active pharmaceutical ingredients and finished dosages.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Health Issues HCR
Federal policy relating to the establishment of a strategic national stockpile for active pharmaceutical ingredients; HR 2853, the BLOCKING Act, provisions relating to amending the Hatch-Waxman Act 180-day exclusivity structure; Federal policy relating to amending the Hatch-Waxman Act's 180 day exclusivity framework to prevent market blockages; Federal policy relating to the establishment of an enhanced approval pathway for complex generic drugs; and Federal policy related to suitability petitions and the submission of Abbreviate New Drug Applications (ANDAs).
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.